Pacer Advisors Inc. Increases Holdings in DexCom, Inc. (NASDAQ:DXCM)

Pacer Advisors Inc. lifted its position in DexCom, Inc. (NASDAQ:DXCM) by 10.9% in the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 49,319 shares of the medical device company’s stock after purchasing an additional 4,831 shares during the period. Pacer Advisors Inc.’s holdings in DexCom were worth $5,592,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in DexCom by 0.3% during the first quarter. Vanguard Group Inc. now owns 44,603,745 shares of the medical device company’s stock worth $6,186,539,000 after buying an additional 136,282 shares during the period. Capital Research Global Investors lifted its holdings in DexCom by 21.4% during the fourth quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock worth $1,898,085,000 after buying an additional 2,695,296 shares during the period. Sands Capital Management LLC lifted its holdings in DexCom by 10.2% during the fourth quarter. Sands Capital Management LLC now owns 15,058,806 shares of the medical device company’s stock worth $1,868,647,000 after buying an additional 1,398,136 shares during the period. Capital World Investors lifted its holdings in DexCom by 130.7% during the fourth quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock worth $1,151,392,000 after buying an additional 5,256,092 shares during the period. Finally, Artisan Partners Limited Partnership lifted its holdings in DexCom by 164.8% during the fourth quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock worth $732,169,000 after buying an additional 3,672,471 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $69.70 on Tuesday. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The company’s 50 day moving average is $77.32 and its 200 day moving average is $108.93. The company has a market cap of $27.72 billion, a PE ratio of 44.97, a price-to-earnings-growth ratio of 2.12 and a beta of 1.18.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.39 by $0.04. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $1.04 billion. During the same quarter in the prior year, the firm posted $0.34 EPS. The business’s quarterly revenue was up 15.3% compared to the same quarter last year. On average, sell-side analysts forecast that DexCom, Inc. will post 1.69 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on DXCM shares. Canaccord Genuity Group restated a “buy” rating and set a $145.00 target price on shares of DexCom in a report on Tuesday, July 23rd. Piper Sandler reissued an “overweight” rating and issued a $90.00 price objective on shares of DexCom in a research report on Monday, August 26th. Barclays lowered their price objective on DexCom from $138.00 to $113.00 and set an “equal weight” rating for the company in a research report on Monday, July 29th. Royal Bank of Canada lowered their price objective on DexCom from $165.00 to $145.00 and set an “outperform” rating for the company in a research report on Friday, July 26th. Finally, Stifel Nicolaus boosted their price target on DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, August 23rd. Seven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $112.25.

Insiders Place Their Bets

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the sale, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Sadie Stern sold 426 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares in the company, valued at approximately $5,217,436.65. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 2,483 shares of company stock worth $201,708. Corporate insiders own 0.30% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.